Dendritic Cells

• 

  Subject Areas on Research

  • A CD91-positive subset of CD11c+ blood dendritic cells: characterization of the APC that functions to enhance adaptive immune responses against CD91-targeted antigens. 
  • A Phase I study of active immunotherapy with carcinoembryonic antigen peptide (CAP-1)-pulsed, autologous human cultured dendritic cells in patients with metastatic malignancies expressing carcinoembryonic antigen. 
  • A Protocol for the Comprehensive Flow Cytometric Analysis of Immune Cells in Normal and Inflamed Murine Non-Lymphoid Tissues. 
  • A RIPK3-caspase 8 complex mediates atypical pro-IL-1β processing. 
  • A comparative study of the generation of dendritic cells from mobilized peripheral blood progenitor cells of patients undergoing high-dose chemotherapy. 
  • A comparison of murine T-cell-depleted adult bone marrow and full-term fetal blood cells in hematopoietic engraftment and immune reconstitution. 
  • A cytokine cocktail directly modulates the phenotype of DC-enriched anti-tumor T cells to convey potent anti-tumor activities in a murine model. 
  • A distinct pattern of cytokine gene expression by human CD83+ blood dendritic cells. 
  • A novel cell-surface molecule expressed by human interdigitating reticulum cells, Langerhans cells, and activated lymphocytes is a new member of the Ig superfamily. 
  • A phase I/IIa clinical trial in stage IV melanoma of an autologous tumor-dendritic cell fusion (dendritoma) vaccine with low dose interleukin-2. 
  • A randomized phase II study of immunization with dendritic cells modified with poxvectors encoding CEA and MUC1 compared with the same poxvectors plus GM-CSF for resected metastatic colorectal cancer. 
  • A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. 
  • A subset of human monocyte-derived dendritic cells expresses high levels of interleukin-12 in response to combined CD40 ligand and interferon-gamma treatment. 
  • A two-phase innate host response to alphavirus infection identified by mRNP-tagging in vivo. 
  • A20 in Myeloid Cells Protects Against Hypertension by Inhibiting Dendritic Cell-Mediated T-Cell Activation. 
  • Abnormal development of thymic dendritic and epithelial cells in human X-linked severe combined immunodeficiency. 
  • Absolute values of dendritic cell subsets in bone marrow, cord blood, and peripheral blood enumerated by a novel method. 
  • Access of HIV-2 to CD169-dependent dendritic cell-mediated trans infection pathway is attenuated. 
  • Acetalated Dextran Microparticles for Codelivery of STING and TLR7/8 Agonists. 
  • Actions of Dendritic Cells in the Kidney during Hypertension. 
  • Actions of immune cells in the hypertensive kidney. 
  • Activated B cells modified by electroporation of multiple mRNAs encoding immune stimulatory molecules are comparable to mature dendritic cells in inducing in vitro antigen-specific T-cell responses. 
  • Activation of arterial wall dendritic cells and breakdown of self-tolerance in giant cell arteritis. 
  • Activation of decidual invariant natural killer T cells promotes lipopolysaccharide-induced preterm birth. 
  • Activation of src-family tyrosine kinases by LPS regulates cytokine production in dendritic cells by controlling AP-1 formation. 
  • Activation of the NLRP3 inflammasome by intracellular poly I:C. 
  • Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. 
  • Acute Liver Damage Associated with Innate Immune Activation in a Small Nonhuman Primate Model of Hepacivirus Infection. 
  • Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. 
  • Adjuvant-free nanofiber vaccine induces in situ lung dendritic cell activation and T_H 17 responses. 
  • Advances and challenges: dendritic cell vaccination strategies for glioblastoma. 
  • Allograft dendritic cell p40 homodimers activate donor-reactive memory CD8+ T cells. 
  • Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. 
  • Alternative translation of osteopontin generates intracellular and secreted isoforms that mediate distinct biological activities in dendritic cells. 
  • An alternative and effective HIV vaccination approach based on inhibition of antigen presentation attenuators in dendritic cells. 
  • Analysis of muscle creatine kinase regulatory elements in recombinant adenoviral vectors. 
  • Analysis of the Rab GTPase Interactome in Dendritic Cells Reveals Anti-microbial Functions of the Rab32 Complex in Bacterial Containment. 
  • Anti-phosphorylcholine-opsonized low-density lipoprotein promotes rapid production of proinflammatory cytokines by dendritic cells and natural killer cells. 
  • Anti-tumor immunity: myeloid leukocytes control the immune landscape. 
  • Antibody response to a T-dependent antigen requires B cell expression of complement receptors. 
  • Antibody, T-cell and dendritic cell immunotherapy for malignant brain tumors. 
  • Antigen-specific NK cell memory in rhesus macaques. 
  • Apoptotic Debris Accumulates on Hematopoietic Cells and Promotes Disease in Murine and Human Systemic Lupus Erythematosus. 
  • Assembling OX40 aptamers on a molecular scaffold to create a receptor-activating aptamer. 
  • Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study. 
  • Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. 
  • B cell depletion reduces the development of atherosclerosis in mice. 
  • Bacterial infection remodels the DNA methylation landscape of human dendritic cells. 
  • Baculovirus-infected insect cells expressing peptide-MHC complexes elicit protective antitumor immunity. 
  • Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches. 
  • Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review. 
  • Blocking CCR7 at the ocular surface impairs the pathogenic contribution of dendritic cells in allergic conjunctivitis. 
  • Blocking ovarian cancer progression by targeting tumor microenvironmental leukocytes. 
  • Blood microbiota diversity determines response of advanced colorectal cancer to chemotherapy combined with adoptive T cell immunotherapy. 
  • Blood-derived inflammatory dendritic cells in lymph nodes stimulate acute T helper type 1 immune responses. 
  • Bone marrow chimeras and c-fms conditional ablation (Mafia) mice reveal an essential role for resident myeloid cells in lipopolysaccharide/TLR4-induced corneal inflammation. 
  • Bone marrow dendritic cell-mediated regulation of TLR and B cell receptor signaling in B cells. 
  • Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. 
  • Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. 
  • Boosting high-intensity focused ultrasound-induced anti-tumor immunity using a sparse-scan strategy that can more effectively promote dendritic cell maturation. 
  • Broadly Neutralizing Antibodies Display Potential for Prevention of HIV-1 Infection of Mucosal Tissue Superior to That of Nonneutralizing Antibodies. 
  • C-C Motif Chemokine Receptor 7 Exacerbates Hypertension Through Effects on T Lymphocyte Trafficking. 
  • CCL5-mediated endogenous antitumor immunity elicited by adoptively transferred lymphocytes and dendritic cell depletion. 
  • CCR2 deficiency, dysregulation of Notch signaling, and spontaneous pulmonary arterial hypertension. 
  • CCR2+ monocyte-derived dendritic cells and exudate macrophages produce influenza-induced pulmonary immune pathology and mortality. 
  • CD1 expression by dendritic cells in human leprosy lesions: correlation with effective host immunity. 
  • CD11c(+)B220(+)Gr-1(+) cells in mouse lymph nodes and spleen display characteristics of plasmacytoid dendritic cells. 
  • CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. 
  • CD169-dependent cell-associated HIV-1 transmission: a driver of virus dissemination. 
  • CD169-mediated trafficking of HIV to plasma membrane invaginations in dendritic cells attenuates efficacy of anti-gp120 broadly neutralizing antibodies. 
  • CD19 expression in B cells is important for suppression of contact hypersensitivity. 
  • CD277 is a negative co-stimulatory molecule universally expressed by ovarian cancer microenvironmental cells. 
  • CD34+CD38-lin- cord blood cells develop into dendritic cells in human thymic stromal monolayers and thymic nodules. 
  • CD4+ T cells elicit host immune responses to MHC class II-negative ovarian cancer through CCL5 secretion and CD40-mediated licensing of dendritic cells. 
  • CD4+/CD56+ hematodermic neoplasm: presentation of 2 cases and review of the concept of an uncommon tumor originated in plasmacytoid dendritic cells expressing CD123 (IL-3 receptor alpha). 
  • CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. 
  • CD83 expression is a sensitive marker of activation required for B cell and CD4+ T cell longevity in vivo. 
  • CD83: a regulatory molecule of the immune system with great potential for therapeutic application. 
  • CEA loaded dendritic cell vaccines. 
  • CX3CR1 deficiency impairs dendritic cell accumulation in arterial intima and reduces atherosclerotic burden. 
  • CX3CR1+ interstitial dendritic cells form a contiguous network throughout the entire kidney. 
  • Calmodulin-dependent kinase IV links Toll-like receptor 4 signaling with survival pathway of activated dendritic cells. 
  • Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. 
  • Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. 
  • Caspase-1-induced pyroptotic cell death. 
  • Cellular FLIP Inhibits Myeloid Cell Activation by Suppressing Selective Innate Signaling. 
  • Cellular and biological therapies of gastrointestinal tumors: overview of clinical trials. 
  • Cellular uptake of neutral phosphorodiamidate morpholino oligomers. 
  • Characterization of Langerin-expressing dendritic cell subsets in the normal cornea. 
  • Chemokine mediated control of dendritic cell migration and function. 
  • Chemokines as adjuvants for immunotherapy: implications for immune activation with CCL3. 
  • Classical Dendritic Cells Mediate Hypertension by Promoting Renal Oxidative Stress and Fluid Retention. 
  • Clinical applications of dendritic cell vaccines. 
  • Clinical immunotherapy for brain tumors. 
  • Combination of DC/CIK adoptive T cell immunotherapy with chemotherapy in advanced non-small-cell lung cancer (NSCLC) patients: a prospective patients' preference-based study (PPPS). 
  • Combined CD4 T-cell and antibody response to human minor histocompatibility antigen DBY after allogeneic stem-cell transplantation. 
  • Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. 
  • Comparative study of α-helical and β-sheet self-assembled peptide nanofiber vaccine platforms: influence of integrated T-cell epitopes. 
  • Contemporary Strategies and Barriers to Transplantation Tolerance. 
  • Continuous DC-CIK infusions restore CD8+ cellular immunity, physical activity and improve clinical efficacy in advanced cancer patients unresponsive to conventional treatments. 
  • Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. 
  • Costimulation molecule expression and subset distribution of blood dendritic cells in normal children and newly diagnosed pediatric leukemia and lymphoma patients. 
  • Cotransfection of DC with TLR4 and MART-1 RNA induces MART-1-specific responses. 
  • Cowpox virus induces interleukin-10 both in vitro and in vivo. 
  • Cowpox virus inhibits human dendritic cell immune function by nonlethal, nonproductive infection. 
  • Creation of tolerogenic human dendritic cells via intracellular CTLA4: a novel strategy with potential in clinical immunosuppression. 
  • Critical role of the tumor suppressor tuberous sclerosis complex 1 in dendritic cell activation of CD4 T cells by promoting MHC class II expression via IRF4 and CIITA. 
  • Cross-talk between T Cells and Hematopoietic Stem Cells during Adoptive Cellular Therapy for Malignant Glioma. 
  • Current status of dendritic cell immunotherapy of malignancies. 
  • Cutting edge: ABIN-1 protects against psoriasis by restricting MyD88 signals in dendritic cells. 
  • Cyclic AMP modulates the functional plasticity of immature dendritic cells by inhibiting Src-like kinases through protein kinase A-mediated signaling. 
  • DC-CIK as a widely applicable cancer immunotherapy. 
  • DNA and RNA modified dendritic cell vaccines. 
  • Decreased interferon-alpha production in HIV-infected patients correlates with numerical and functional deficiencies in circulating type 2 dendritic cell precursors. 
  • Defective dendritic cell maturation in a child with nucleotide excision repair deficiency and CD4 lymphopenia. 
  • Defects in intracellular trafficking of fungal cell wall synthases lead to aberrant host immune recognition. 
  • Delineation of the role of platelet-activating factor in the immunoglobulin G2 antibody response. 
  • Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy. 
  • Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 
  • Dendritic Cell-Activating Magnetic Nanoparticles Enable Early Prediction of Antitumor Response with Magnetic Resonance Imaging. 
  • Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. 
  • Dendritic Cells Enhance Polyfunctionality of Adoptively Transferred T Cells That Target Cytomegalovirus in Glioblastoma. 
  • Dendritic Cells Interpret Haptotactic Chemokine Gradients in a Manner Governed by Signal-to-Noise Ratio and Dependent on GRK6. 
  • Dendritic cell CD83: a therapeutic target or innocent bystander? 
  • Dendritic cell gene therapy. 
  • Dendritic cell maturation in active immunotherapy strategies. 
  • Dendritic cell recovery following nonmyeloablative allogeneic stem cell transplants. 
  • Dendritic cell responses to early murine cytomegalovirus infection: subset functional specialization and differential regulation by interferon alpha/beta. 
  • Dendritic cell transmigration through brain microvessel endothelium is regulated by MIP-1alpha chemokine and matrix metalloproteinases. 
  • Dendritic cell vaccines targeting survivin in head and neck cancer. 
  • Dendritic cell vaccines. 
  • Dendritic cell-based immunization for cancer therapy. 
  • Dendritic cell-based immunotherapy. 
  • Dendritic cell-expanded, islet-specific CD4+ CD25+ CD62L+ regulatory T cells restore normoglycemia in diabetic NOD mice. 
  • Dendritic cell-tumor cell fusion vaccines. 
  • Dendritic cell/macrophage precursors capture exogenous antigen for MHC class I presentation by dendritic cells. 
  • Dendritic cells activate antitumor immunity for malignant intracranial germ cell tumor: a case report. 
  • Dendritic cells and the immunopathogenesis of idiopathic inflammatory myopathies. 
  • Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response. 
  • Dendritic cells engineered to secrete anti-GITR antibodies are effective adjuvants to dendritic cell-based immunotherapy. 
  • Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma. 
  • Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. 
  • Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. 
  • Dendritic cells pulsed with a tumor-specific peptide induce long-lasting immunity and are effective against murine intracerebral melanoma. 
  • Dendritic cells pulsed with pancreatic cancer total tumor RNA generate specific antipancreatic cancer T cells. 
  • Dendritic cells stimulated with Actinobacillus actinomycetemcomitans elicit rapid gamma interferon responses by natural killer cells. 
  • Dendritic cells with TGF-beta1 differentiate naive CD4+CD25- T cells into islet-protective Foxp3+ regulatory T cells. 
  • Dendritic cells/natural killer cross-talk: a novel target for human immunodeficiency virus type-1 protease inhibitors. 
  • Dendritic-NK cell interactions in P. gingivalis-specific responses. 
  • Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. 
  • Depletion of human regulatory T cells specifically enhances antigen-specific immune responses to cancer vaccines. 
  • Derivation of injury-responsive dendritic cells for acute brain targeting and therapeutic protein delivery in the stroke-injured rat. 
  • Detection of differentially abundant cell subpopulations in scRNA-seq data. 
  • Diacylglycerol kinase zeta regulates microbial recognition and host resistance to Toxoplasma gondii. 
  • Diacylglycerol kinases in immune cell function and self-tolerance. 
  • Dietary Salt Exacerbates Experimental Colitis. 
  • Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. 
  • Differential expression of platelet-activating factor acetylhydrolase in macrophages and monocyte-derived dendritic cells. 
  • Direct vaccination with tumor cells killed with ICP4-deficient HSVd120 elicits effective antitumor immunity. 
  • Donor-derived, tolerogenic dendritic cells suppress immune rejection in the indirect allosensitization-dominant setting of corneal transplantation. 
  • Dressing up Nanoparticles: A Membrane Wrap to Induce Formation of the Virological Synapse. 
  • ER Stress Sensor XBP1 Controls Anti-tumor Immunity by Disrupting Dendritic Cell Homeostasis. 
  • Early-onset monocyte-B-natural killer-dendritic cells' deficiency successfully treated with hematopoietic stem cell transplantation. 
  • Editorial: Local Immune Modulation of Macrophages and Dendritic Cells - Local Matters. 
  • Effect of cytofectins on the immune response of murine macrophages to mammalian DNA. 
  • Efficient dendritic cell priming of T lymphocytes depends on the extracellular matrix protein mindin. 
  • Emerging clinical applications of RNA. 
  • Endothelial heparan sulfate controls chemokine presentation in recruitment of lymphocytes and dendritic cells to lymph nodes. 
  • Engagement of the type I interferon receptor on dendritic cells inhibits T helper 17 cell development: role of intracellular osteopontin. 
  • Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. 
  • Enhanced dendritic cell antigen presentation in RNA-based immunotherapy. 
  • Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. 
  • Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. 
  • Enhancing dendritic cell-based vaccination for highly aggressive glioblastoma. 
  • Enhancing the immunostimulatory function of dendritic cells by transfection with mRNA encoding OX40 ligand. 
  • Epigallocatechin gallate affects human dendritic cell differentiation and maturation. 
  • Ex vivo generation of dendritic cells from cryopreserved, post-induction chemotherapy, mobilized leukapheresis from pediatric patients with medulloblastoma. 
  • Expression of A20 by dendritic cells preserves immune homeostasis and prevents colitis and spondyloarthritis. 
  • Expression of cytokine mRNA in murine splenic dendritic cells and better induction of T cell-derived cytokines by dendritic cells than by macrophages during in vitro costimulation assay using specific antigens. 
  • Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets. 
  • GPI-defective monocytes from paroxysmal nocturnal hemoglobinuria patients show impaired in vitro dendritic cell differentiation. 
  • GRP94 (gp96) and GRP94 N-terminal geldanamycin binding domain elicit tissue nonrestricted tumor suppression. 
  • Gaining ground on a cure through synergy: combining checkpoint inhibitors with cancer vaccines. 
  • Galectin-1 is essential for the induction of MOG35-55 -based intravenous tolerance in experimental autoimmune encephalomyelitis. 
  • Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy. 
  • Generation of Tumor Targeted Dendritic Cell Vaccines with Improved Immunogenic and Migratory Phenotype. 
  • Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-alpha for use in cancer immunotherapy. 
  • Genetically stable poliovirus vectors activate dendritic cells and prime antitumor CD8 T cell immunity. 
  • Glycosphingolipid-functionalized nanoparticles recapitulate CD169-dependent HIV-1 uptake and trafficking in dendritic cells. 
  • Graft hyporeactivity induced by donor-derived dendritic cell progenitors. 
  • Graft hyporeactivity induced by immature donor-derived dendritic cells. 
  • HER2 dendritic cell vaccines. 
  • HER2-LAMP vaccines effectively traffic to endolysosomal compartments and generate enhanced polyfunctional T cell responses that induce complete tumor regression. 
  • HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. 
  • HIV-1 gp120 induces anergy in naive T lymphocytes through CD4-independent protein kinase-A-mediated signaling. 
  • HIV-1 incorporation of host-cell-derived glycosphingolipid GM3 allows for capture by mature dendritic cells. 
  • HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. 
  • HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge. 
  • HIV. A clever hijacker of the immune system. 
  • Harnessing virus tropism for dendritic cells for vaccine design. 
  • Heat shock proteins HSP27 and HSP70 are present in the skin and are important mediators of allergic contact hypersensitivity. 
  • Helicobacter pylori induces apoptosis of human monocytes but not monocyte-derived dendritic cells: role of the cag pathogenicity island. 
  • Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation. 
  • Heparin enhances uptake of platelet factor 4/heparin complexes by monocytes and macrophages. 
  • Heparin modifies the immunogenicity of positively charged proteins. 
  • Hepatic enrichment and activation of myeloid dendritic cells during chronic hepatitis C virus infection. 
  • Hepatic stellate cells undermine the allostimulatory function of liver myeloid dendritic cells via STAT3-dependent induction of IDO. 
  • High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted Mycobacterium tuberculosis epitopes. 
  • Histiocytic/dendritic cell transformation of B-cell neoplasms: pathologic evidence of lineage conversion in differentiated hematolymphoid malignancies. 
  • Human Immunodeficiency Virus C.1086 Envelope gp140 Protein Boosts following DNA/Modified Vaccinia Virus Ankara Vaccination Fail To Enhance Heterologous Anti-V1V2 Antibody Response and Protection against Clade C Simian-Human Immunodeficiency Virus Challenge. 
  • Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. 
  • Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. 
  • Human dendritic cells, pulsed with either melanoma tumor cell lysates or the gp100 peptide(280-288), induce pairs of T-cell cultures with similar phenotype and lytic activity. 
  • Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. 
  • Human spleen contains phenotypic subsets of macrophages and dendritic cells that occupy discrete microanatomic locations. 
  • IFN-beta inhibits human Th17 cell differentiation. 
  • IFN-beta1a inhibits the secretion of Th17-polarizing cytokines in human dendritic cells via TLR7 up-regulation. 
  • IL-12-Dependent Cytomegalovirus-Specific CD4+ T Cell Proliferation, T-bet Induction, and Effector Multifunction during Primary Infection Are Key Determinants for Early Immune Control. 
  • Identification of a tissue-specific, C/EBPβ-dependent pathway of differentiation for murine peritoneal macrophages. 
  • Identification of myeloid cell subsets in murine lungs using flow cytometry. 
  • IgG-Immune Complexes Promote B Cell Memory by Inducing BAFF. 
  • Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. 
  • Immune evasion pathways and the design of dendritic cell-based cancer vaccines. 
  • Immune heterogeneity in neuroinflammation: dendritic cells in the brain. 
  • Immune responses to dengue virus in the skin. 
  • Immune synapses between mast cells and γδ T cells limit viral infection. 
  • Immunodominant liver-specific expression suppresses transgene-directed immune responses in murine pompe disease. 
  • Immunogenic cancer cell death selectively induced by near infrared photoimmunotherapy initiates host tumor immunity. 
  • Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. 
  • Immunogenicity of dendritic-tumor fusion hybrids and their utility in cancer immunotherapy. 
  • Immunological and clinical responses in metastatic renal cancer patients vaccinated with tumor RNA-transfected dendritic cells. 
  • Immunopathogenesis of juvenile dermatomyositis. 
  • Immunophenotyping of chimeric cells in localized scleroderma. 
  • Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. 
  • Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. 
  • Immunotherapy against angiogenesis-associated targets: evidence and implications for the treatment of malignant glioma. 
  • Immunotherapy approaches in the treatment of malignant brain tumors. 
  • Immunotherapy for osteosarcoma: Where do we go from here? 
  • Immunotherapy of cancer using dendritic cells. 
  • Immunotherapy of cancer with dendritic cell-based vaccines. 
  • Immunotherapy of cancer with dendritic-cell-based vaccines. 
  • Immunotherapy of established murine squamous cell carcinoma using fused dendritic-tumor cell hybrids. 
  • Immunotherapy using allogeneic squamous cell tumor-dendritic cell fusion hybrids. 
  • Immunotherapy with autologous, human dendritic cells transfected with carcinoembryonic antigen mRNA. 
  • Impact of anti-CD25 monoclonal antibody on dendritic cell-tumor fusion vaccine efficacy in a murine melanoma model. 
  • Improving defences at the portal of HIV entry: mucosal and innate immunity. 
  • In situ stimulation of CD40 and Toll-like receptor 3 transforms ovarian cancer-infiltrating dendritic cells from immunosuppressive to immunostimulatory cells. 
  • In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. 
  • In vivo activation of antigen-specific CD4 T cells. 
  • In vivo dendritic cell tracking using fluorescence lifetime imaging and near-infrared-emissive polymersomes. 
  • Inducing enhanced immunogenic cell death with nanocarrier-based drug delivery systems for pancreatic cancer therapy. 
  • Induction and Characterization of the Allergic Eye Disease Mouse Model. 
  • Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. 
  • Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. 
  • Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. 
  • Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. 
  • Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. 
  • Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. 
  • Induction of human dendritic cell maturation using transfection with RNA encoding a dominant positive toll-like receptor 4. 
  • Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. 
  • Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. 
  • Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. 
  • Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. 
  • Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. 
  • Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. 
  • Induction of type I IFN is required for overcoming tumor-specific T-cell tolerance after stem cell transplantation. 
  • Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. 
  • Inflammatory Th1 and Th17 in the Intestine Are Each Driven by Functionally Specialized Dendritic Cells with Distinct Requirements for MyD88. 
  • Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells. 
  • Inherited human Caspase 10 mutations underlie defective lymphocyte and dendritic cell apoptosis in autoimmune lymphoproliferative syndrome type II. 
  • Inhibition of Human Dendritic Cell ER Stress Response Reduces T Cell Alloreactivity Yet Spares Donor Anti-tumor Immunity. 
  • Inhibition of NF-kappa B and oxidative pathways in human dendritic cells by antioxidative vitamins generates regulatory T cells. 
  • Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. 
  • Inhibition of murine dendritic cell activation by synthetic phosphorothioate oligodeoxynucleotides. 
  • Inhibitory effect of PRO 2000, a candidate microbicide, on dendritic cell-mediated human immunodeficiency virus transfer. 
  • Initial phase I/IIa trial results of an autologous tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with solid tumors. 
  • Injection of immature dendritic cells into adjuvant-treated skin obviates the need for ex vivo maturation. 
  • Innate Functions of Dendritic Cell Subsets in Cardiac Allograft Tolerance. 
  • Interferon-Inducible CD169/Siglec1 Attenuates Anti-HIV-1 Effects of Alpha Interferon. 
  • Interferon-inducible mechanism of dendritic cell-mediated HIV-1 dissemination is dependent on Siglec-1/CD169. 
  • Interferon-γ secretion by t(9;22) acute lymphoblastic leukemia-derived dendritic cells. 
  • Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. 
  • Intrinsic Defects in B Cell Development and Differentiation, T Cell Exhaustion and Altered Unconventional T Cell Generation Characterize Human Adenosine Deaminase Type 2 Deficiency. 
  • Inverse correlation of maturity and antibacterial activity in human dendritic cells. 
  • Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. 
  • Involvement of an ATP-dependent peptide chaperone in cross-presentation after DNA immunization. 
  • Isolation and generation of human dendritic cells. 
  • Isolation and generation of human dendritic cells. 
  • LAB/NTAL facilitates fungal/PAMP-induced IL-12 and IFN-γ production by repressing β-catenin activation in dendritic cells. 
  • LRRK2 and Rab10 coordinate macropinocytosis to mediate immunological responses in phagocytes. 
  • Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function. 
  • Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity. 
  • Lin^- CCR2⁺ hematopoietic stem and progenitor cells overcome resistance to PD-1 blockade. 
  • Linking immune responses with fibrosis in allergic eye disease. 
  • Lipid bodies containing oxidatively truncated lipids block antigen cross-presentation by dendritic cells in cancer. 
  • Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2. 
  • Lipopolysaccharide-induced expression of TRAIL promotes dendritic cell differentiation. 
  • Local secretion of IL-12 augments the therapeutic impact of dendritic cell-tumor cell fusion vaccination. 
  • Long noncoding RNA MIR4435-2HG enhances metabolic function of myeloid dendritic cells from HIV-1 elite controllers. 
  • Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination. 
  • Longitudinal peripheral blood lymphocyte subsets correlate with decreased disease activity in juvenile dermatomyositis. 
  • Lung effector memory and activated CD4+ T cells display enhanced proliferation in surfactant protein A-deficient mice during allergen-mediated inflammation. 
  • M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer. 
  • MCA106 fibrosarcoma cells transduced with granulocyte/macrophage colony-stimulating factor are not superior to the wild-type cells in suppressing the growth of hepatic metastases. 
  • MRGPR-mediated activation of local mast cells clears cutaneous bacterial infection and protects against reinfection. 
  • Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. 
  • Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. 
  • Mapping the SARS-CoV-2 spike glycoprotein-derived peptidome presented by HLA class II on dendritic cells. 
  • Mast cell interleukin-10 drives localized tolerance in chronic bladder infection. 
  • Mast cells augment adaptive immunity by orchestrating dendritic cell trafficking through infected tissues. 
  • Mechanisms of immune stimulation by bacterial DNA. 
  • Melanoma immunotherapy using mature DCs expressing the constitutive proteasome. 
  • Melanoma, a tumor based on a mutant stem cell? 
  • Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy. 
  • Metastatic breast cancers have reduced immune cell recruitment but harbor increased macrophages relative to their matched primary tumors. 
  • Mice lacking expression of secondary lymphoid organ chemokine have defects in lymphocyte homing and dendritic cell localization. 
  • Mice lacking expression of the chemokines CCL21-ser and CCL19 (plt mice) demonstrate delayed but enhanced T cell immune responses. 
  • Mice that overexpress CC chemokine ligand 2 in their lungs show increased protective immunity to infection with Mycobacterium bovis bacille Calmette-Guérin. 
  • Migration of human dendritic cells after injection in patients with metastatic malignancies. 
  • Mobilization of dendritic cells from patients with breast cancer into peripheral blood stem cell leukapheresis samples using Flt-3-Ligand and G-CSF or GM-CSF. 
  • Mobilization of dendritic cells in cancer patients treated with granulocyte colony-stimulating factor and chemotherapy. 
  • Molecular control of steady-state dendritic cell maturation and immune homeostasis. 
  • Monocyte differentiation in localized juvenile periodontitis is skewed toward the dendritic cell phenotype. 
  • Monocytes as a Cellular Vaccine Platform to Induce Antitumor Immunity. 
  • Multilocular thymic cysts in children with human immunodeficiency virus infection: clinical and pathologic aspects. 
  • Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. 
  • Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. 
  • Mycobacterium tuberculosis infection induces il12rb1 splicing to generate a novel IL-12Rbeta1 isoform that enhances DC migration. 
  • NK cell activation by dendritic cell vaccine: a mechanism of action for clinical activity. 
  • NLRC3 expression in dendritic cells attenuates CD4+ T cell response and autoimmunity. 
  • Nanomolecular targeting of dendritic cells for ovarian cancer therapy. 
  • Natural IgM Switches the Function of Lipopolysaccharide-Activated Murine Bone Marrow-Derived Dendritic Cells to a Regulatory Dendritic Cell That Suppresses Innate Inflammation. 
  • New roles for mast cells in pathogen defense and allergic disease. 
  • New twists to an old story: novel concepts in the pathogenesis of allergic eye disease. 
  • Noncanonical autophagy in dermal dendritic cells mediates immunosuppressive effects of UV exposure. 
  • Novel antigen-presenting cell imparts Treg-dependent tolerance to gut microbiota. 
  • Ocular mucosal CD11b+ and CD103+ mouse dendritic cells under normal conditions and in allergic immune responses. 
  • Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma. 
  • Oncostatin M enhances CCL21 expression by microvascular endothelial cells and increases the efficiency of dendritic cell trafficking to lymph nodes. 
  • Optimization of the sequence of antigen loading and CD40-ligand-induced maturation of dendritic cells. 
  • Optimization of vaccine responses with an E1, E2b and E3-deleted Ad5 vector circumvents pre-existing anti-vector immunity. 
  • Optimizing dendritic cell function by genetic modification. 
  • Osteopontin expression is essential for interferon-alpha production by plasmacytoid dendritic cells. 
  • Ovarian cancer progression is controlled by phenotypic changes in dendritic cells. 
  • P-selectin glycoprotein ligand-1 is broadly expressed in cells of myeloid, lymphoid, and dendritic lineage and in some nonhematopoietic cells. 
  • PLG scaffold delivered antigen-specific regulatory T cells induce systemic tolerance in autoimmune diabetes. 
  • Paracrine Wnt5a-β-Catenin Signaling Triggers a Metabolic Program that Drives Dendritic Cell Tolerization. 
  • Pathogenesis of myositis in children. 
  • Peripheral blood dendritic cells, but not monocyte-derived dendritic cells, can augment human NK cell function. 
  • Perivascular dendritic cells elicit anaphylaxis by relaying allergens to mast cells via microvesicles. 
  • Permanent survival of fully MHC-mismatched islet allografts by targeting a single chemokine receptor pathway. 
  • Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 
  • Phase I study of immunization with dendritic cells modified with fowlpox encoding carcinoembryonic antigen and costimulatory molecules. 
  • Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. 
  • Phenotypic and functional characterization of cytotoxic T lymphocytes by flow cytometry. 
  • Phenotypic and functional maturation of dendritic cells mediated by heparan sulfate. 
  • Phenotypic and immunologic comparison of clade B transmitted/founder and chronic HIV-1 envelope glycoproteins. 
  • Phenotypic properties of transmitted founder HIV-1. 
  • Phenotypic subpopulations of macrophages and dendritic cells in human spleen. 
  • Phenotyping Tumor-Associated Macrophages. 
  • Physiology and therapeutics of vascular endothelial growth factor in tumor immunosuppression. 
  • Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. 
  • Plexin-B2 and Plexin-D1 in dendritic cells: expression and IL-12/IL-23p40 production. 
  • Polyethylenimine-based siRNA nanocomplexes reprogram tumor-associated dendritic cells via TLR5 to elicit therapeutic antitumor immunity. 
  • Precision cancer immunotherapy: optimizing dendritic cell-based strategies to induce tumor antigen-specific T-cell responses against individual patient tumors. 
  • Preconditioning Vaccine Sites for mRNA-Transfected Dendritic Cell Therapy and Antitumor Efficacy. 
  • Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. 
  • Preexisting infection with human T-cell lymphotropic virus type 2 neither exacerbates nor attenuates simian immunodeficiency virus SIVmac251 infection in macaques. 
  • Preoperative mobilization of circulating dendritic cells by Flt3 ligand administration to patients with metastatic colon cancer. 
  • Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. 
  • Preparation of peptide-loaded dendritic cells for cancer immunotherapy. 
  • Primary germinal center-resident T follicular helper cells are a physiologically distinct subset of CXCR5hiPD-1hi T follicular helper cells. 
  • Programming human dendritic cells with mRNA. 
  • Programming the magnitude and persistence of antibody responses with innate immunity. 
  • Prospective study of cyclophosphamide, thiotepa, carboplatin combined with adoptive DC-CIK followed by metronomic cyclophosphamide therapy as salvage treatment for triple negative metastatic breast cancers patients (aged <45). 
  • Protease-activated receptor-2 signaling triggers dendritic cell development. 
  • Protective immunity in recurrent Staphylococcus aureus infection reflects localized immune signatures and macrophage-conferred memory. 
  • Pulsing of dendritic cells with cell lysates from either B16 melanoma or MCA-106 fibrosarcoma yields equally effective vaccines against B16 tumors in mice. 
  • RNA as performance-enhancers for dendritic cells. 
  • RNA transfected dendritic cells as cancer vaccines. 
  • RNA-Based Vaccines in Cancer Immunotherapy. 
  • RNA-transfected dendritic cells in cancer immunotherapy. 
  • RNA-transfected dendritic cells. 
  • Rapamycin-conditioned donor dendritic cells differentiate CD4CD25Foxp3 T cells in vitro with TGF-beta1 for islet transplantation. 
  • Re-engineered CD40 receptor enables potent pharmacological activation of dendritic-cell cancer vaccines in vivo. 
  • Recent areas of development for dendritic cell vaccines. 
  • Recent developments in therapeutic cancer vaccines. 
  • Receptor signaling in immune cell development and function. 
  • Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. 
  • Recruited exudative macrophages selectively produce CXCL10 after noninfectious lung injury. 
  • Redundancy renders the glycoprotein 96 receptor scavenger receptor A dispensable for cross priming in vivo. 
  • Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. 
  • Regulation of T-helper-cell lineage development by osteopontin: the inside story. 
  • Regulatory B cells (B10 cells) and regulatory T cells have independent roles in controlling experimental autoimmune encephalomyelitis initiation and late-phase immunopathogenesis. 
  • Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. 
  • Renal effects of cytokines in hypertension. 
  • Replication-attenuated Human Adenoviral Type 4 vectors elicit capsid dependent enhanced innate immune responses that are partially dependent upon interactions with the complement system. 
  • Reprogramming tumor-associated dendritic cells in vivo using miRNA mimetics triggers protective immunity against ovarian cancer. 
  • Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9. 
  • Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma. 
  • Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. 
  • Review. Colon cancer vaccines: an update. 
  • Rhbdd3 controls autoimmunity by suppressing the production of IL-6 by dendritic cells via K27-linked ubiquitination of the regulator NEMO. 
  • Role of C-C motif ligand 2 and C-C motif receptor 2 in murine pulmonary graft-versus-host disease after lipopolysaccharide inhalations. 
  • Role of CCR7 in facilitating direct allosensitization and regulatory T-cell function in high-risk corneal transplantation. 
  • Role of Toll-like receptor-driven innate immunity in thoracic organ transplantation. 
  • Role of Tumor-Mediated Dendritic Cell Tolerization in Immune Evasion. 
  • Role of chaperones in antigen processing. 
  • Role of dendritic cell metabolic reprogramming in tumor immune evasion. 
  • Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. 
  • Role of macrophages in restricting herpes simplex virus type 1 growth after ocular infection. 
  • Role of natural killer cell function in dendritic cell-based vaccines. 
  • S1P-Dependent trafficking of intracellular yersinia pestis through lymph nodes establishes Buboes and systemic infection. 
  • SAMMA, a mandelic acid condensation polymer, inhibits dendritic cell-mediated HIV transmission. 
  • SREC-I, a type F scavenger receptor, is an endocytic receptor for calreticulin. 
  • Salmonella efficiently enter and survive within cultured CD11c+ dendritic cells initiating cytokine expression. 
  • Satb1 Overexpression Drives Tumor-Promoting Activities in Cancer-Associated Dendritic Cells. 
  • Secondary allergic T cell responses are regulated by dendritic cell-derived thrombospondin-1 in the setting of allergic eye disease. 
  • Selections of appropriate regimen of high-dose chemotherapy combined with adoptive cellular therapy with dendritic and cytokine-induced killer cells improved progression-free and overall survival in patients with metastatic breast cancer: reargument of such contentious therapeutic preferences. 
  • Selective modification of antigen-specific T cells by RNA electroporation. 
  • Sequential delivery of maturation stimuli increases human dendritic cell IL-12 production and enhances tumor antigen-specific immunogenicity. 
  • Severe adverse immunologic reaction in a patient with glioblastoma receiving autologous dendritic cell vaccines combined with GM-CSF and dose-intensified temozolomide. 
  • Significance of regional draining lymph nodes in the development of tumor immunity: implications for cancer immunotherapy. 
  • Simian immunodeficiency virus-Vpx for improving integrase defective lentiviral vector-based vaccines. 
  • Simvastatin inhibits IFN regulatory factor 4 expression and Th17 cell differentiation in CD4+ T cells derived from patients with multiple sclerosis. 
  • Simvastatin inhibits secretion of Th17-polarizing cytokines and antigen presentation by DCs in patients with relapsing remitting multiple sclerosis. 
  • Soluble B7-H1: differences in production between dendritic cells and T cells. 
  • Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. 
  • Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. 
  • Spontaneous formation of germinal centers in autoimmune mice. 
  • State-of-the-art of regulatory dendritic cells in cancer. 
  • Status of colon cancer vaccines. [An interview with Michael Morse by H&O]. 
  • Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. 
  • Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in Combination with Replication-Competent NYVAC-KC for Induction of Env-Specific Antibody and T Cell Responses. 
  • Supramolecular peptide vaccines: tuning adaptive immunity. 
  • Surface availability of beta-glucans is critical determinant of host immune response to Cladosporium cladosporioides. 
  • Surfactant protein-A inhibits mycoplasma-induced dendritic cell maturation through regulation of HMGB-1 cytokine activity. 
  • Synergy between tumor immunotherapy and antiangiogenic therapy. 
  • Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. 
  • T-cell-directed cancer vaccines: the melanoma model. 
  • Targeting B-cells mitigates autoimmune diabetes in NOD mice: what is plan B? 
  • Targeting molecular and cellular inhibitory mechanisms for improvement of antitumor memory responses reactivated by tumor cell vaccine. 
  • Tat-functionalized near-infrared emissive polymersomes for dendritic cell labeling. 
  • Telomerase mRNA-transfected dendritic cells stimulate antigen-specific CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. 
  • Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients. 
  • Th17 Immunity in the Colon Is Controlled by Two Novel Subsets of Colon-Specific Mononuclear Phagocytes. 
  • The In Vitro Differentiation of Human CD141+CLEC9A+ Dendritic Cells from Mobilized Peripheral Blood CD34+ Hematopoietic Stem Cells. 
  • The Mitochondrial Phosphatase PGAM5 Is Dispensable for Necroptosis but Promotes Inflammasome Activation in Macrophages. 
  • The NLRP3 inflammasome detects encephalomyocarditis virus and vesicular stomatitis virus infection. 
  • The Preuss Foundation Seminar on vaccine therapy for malignant primary brain tumors. February 15-17, 1998, La Jolla, Calif. 
  • The Ubiquitin-Modifying Enzyme A20 Terminates C-Type Lectin Receptor Signals and Is a Suppressor of Host Defense against Systemic Fungal Infection. 
  • The bridge between dendritic cells and asthma. 
  • The danger within. 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The feasibility and safety of immunotherapy with dendritic cells loaded with CEA mRNA following neoadjuvant chemoradiotherapy and resection of pancreatic cancer. 
  • The function and affinity maturation of HIV-1 gp120-specific monoclonal antibodies derived from colostral B cells. 
  • The history, evolution, and clinical use of dendritic cell-based immunization strategies in the therapy of brain tumors. 
  • The modulation of dendritic cell integrin binding and activation by RGD-peptide density gradient substrates. 
  • The necroptosis adaptor RIPK3 promotes injury-induced cytokine expression and tissue repair. 
  • The prognostic value of peripheral CD4+CD25+ T lymphocytes among early stage and triple negative breast cancer patients receiving dendritic cells-cytokine induced killer cells infusion. 
  • The prolyl isomerase Pin1 modulates development of CD8+ cDC in mice. 
  • The role of IL-13 in the generation of dendritic cells in vitro. 
  • The role of dendritic cell precursors in tumour vasculogenesis. 
  • The role of hyaluronan degradation products as innate alloimmune agonists. 
  • The role of innate immunity in the induction of autoimmunity. 
  • The scaffold-dependent function of RIPK1 in dendritic cells promotes injury-induced colitis. 
  • The use of self-adjuvanting nanofiber vaccines to elicit high-affinity B cell responses to peptide antigens without inflammation. 
  • Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice. 
  • Therapeutic vaccine generated by electrofusion of dendritic cells and tumour cells. 
  • Three populations of cells with dendritic morphology exist in peripheral blood, only one of which is infectable with human immunodeficiency virus type 1. 
  • Tolerance mechanisms and recent progress. 
  • Toll-like receptor agonists as third signals for dendritic cell-tumor fusion vaccines. 
  • Toward effective immunotherapy for the treatment of malignant brain tumors. 
  • Transcription factor E2-2 is an essential and specific regulator of plasmacytoid dendritic cell development. 
  • Transduction of human antigen-presenting cells with integrase-defective lentiviral vector enables functional expansion of primed antigen-specific CD8(+) T cells. 
  • Transfection efficiency and transgene expression kinetics of mRNA delivered in naked and nanoparticle format. 
  • Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. 
  • Transmembrane domain membrane proximal external region but not surface unit-directed broadly neutralizing HIV-1 antibodies can restrict dendritic cell-mediated HIV-1 trans-infection. 
  • Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. 
  • Tumor lysate particle loaded dendritic cell vaccine: preclinical testing of a novel personalized cancer vaccine. 
  • Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients. 
  • Tumor-dendritic cell fusion as a basis for cancer immunotherapy. 
  • Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. 
  • Tumor-specific recognition of human myeloma cells by idiotype-induced CD8(+) T cells. 
  • Type 1 Angiotensin Receptors on CD11c-Expressing Cells Protect Against Hypertension by Regulating Dendritic Cell-Mediated T Cell Activation. 
  • Type B CpG oligodeoxynucleotides induce Th1 responses to peanut antigens: modulation of sensitization and utility in a truncated immunotherapy regimen in mice. 
  • Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells. 
  • Type I interferon signaling restrains IL-10R+ colonic macrophages and dendritic cells and leads to more severe Salmonella colitis. 
  • Type III TGF-β receptor downregulation generates an immunotolerant tumor microenvironment. 
  • Tyrosine phosphorylation-independent regulation of lipopolysaccharide-mediated response by the transmembrane adaptor protein LAB. 
  • Update on multi-center clinical trials in the United States. 
  • Vaccination against the forkhead family transcription factor Foxp3 enhances tumor immunity. 
  • Vaccination with dendritic cells inhibits the growth of hepatic metastases in B6 mice. 
  • Vaccine therapy in non-small-cell lung cancer. 
  • Vaccine-Induced Memory CD8+ T Cells Provide Clinical Benefit in HER2 Expressing Breast Cancer: A Mouse to Human Translational Study. 
  • Vascular endothelial growth factor and immunosuppression in cancer: current knowledge and potential for new therapy. 
  • Vascular endothelial growth factor impairs the functional ability of dendritic cells through Id pathways. 
  • Vascular leukocytes: a population with angiogenic and immunossuppressive properties highly represented in ovarian cancer. 
  • Virus particle release from glycosphingolipid-enriched microdomains is essential for dendritic cell-mediated capture and transfer of HIV-1 and henipavirus. 
  • Whole blood cells loaded with messenger RNA as an anti-tumor vaccine. 
  • [Study of immunoregulation of dendritic cells in allergic rhinitis]. 
• 

  Keywords of People

  • Bao, Evangeline, Student, Basic Science Departments
  • Buckley, Rebecca Hatcher, James Buren Sidbury Distinguished Professor Emeritus of Pediatrics, in the School of Medicine, Pediatrics, Allergy and Immunology
  • Chen, Jun, Professor of Medicine, Duke Cancer Institute
  • Gunn, Michael Dee, Professor of Medicine, Integrative Immunobiology
  • Hanks, Brent A., Associate Professor of Medicine, Pharmacology & Cancer Biology
  • Kelsoe, Garnett H., James B. Duke Distinguished Professor of Immunology, Integrative Immunobiology
  • Khandelwal, Sanjay, Assistant Professor in Medicine, Medicine, Hematology
  • Lee, Walter T, Professor of Head and Neck Surgery & Communication Sciences, Radiation Oncology
  • MacLeod, Amanda S, Adjunct Associate Professor in the Department of Dermatology, Integrative Immunobiology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Shinohara, Mari L., Professor of Integrative Immunobiology, Cell Biology
  • Stoecker, Maggie Marie, Assistant Professor of Pathology, Pathology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology
  • Zhong, Xiaoping, Professor of Pediatrics, Integrative Immunobiology